Chambrelant Isabelle, Kuntz Laure, Le Fèvre Clara, Jarnet Delphine, Jacob Julian, Noël Georges
Department of Radiation Oncology, Institut de Cancérologie Strasbourg Europe (ICANS), UNICANCER, Paul Strauss Comprehensive Cancer Center, 67200 Strasbourg, France.
Department of Medical Physics, Institut de Cancérologie Strasbourg Europe (ICANS), UNICANCER, Paul Strauss Comprehensive Cancer Center, 67200 Strasbourg, France.
Cancers (Basel). 2024 Jul 21;16(14):2602. doi: 10.3390/cancers16142602.
Brain metastases (BMs) frequently occur in cancer patients, and stereotactic radiation therapy (SRT) is a preferred treatment option. In this retrospective study, we analyzed patients treated by SRT for a single BM during their first SRT session and we compared two subgroups: "Cohort 1" with patients did not undergo cerebral re-irradiation and "Cohort 2" with patients received at least one subsequent SRT session for cerebral recurrence.
We included patients who received SRT for a single BM between January 2010 and June 2020. Cohort 1 comprised 152 patients, and Cohort 2 had 46 patients.
Cohort 2 exhibited younger patients with higher Karnofsky performance status (KPS). Median overall survival was considerably longer in Cohort 2 (21.8 months) compared to Cohort 1 (6.1 months). Local and cerebral recurrence rates were significantly higher in Cohort 2 ( < 0.001), attributed to patient selection and longer survival. The combined score of age and KPS proved to be a predictive factor for survival, with patients under 65 years of age and KPS > 80 showing the best survival rates in the overall population.
This retrospective study highlights that the combined score of age and KPS can predict better survival, especially for patients under 65 years with a KPS score above 80. Further research involving larger and more diverse populations is essential to validate and expand upon these findings.
脑转移瘤(BMs)在癌症患者中频繁出现,立体定向放射治疗(SRT)是一种首选的治疗选择。在这项回顾性研究中,我们分析了在首次SRT疗程中接受SRT治疗单个脑转移瘤的患者,并比较了两个亚组:“队列1”为未接受脑部再照射的患者,“队列2”为因脑部复发至少接受过一次后续SRT疗程的患者。
我们纳入了2010年1月至2020年6月期间接受SRT治疗单个脑转移瘤的患者。队列1包括152例患者,队列2有46例患者。
队列2的患者更年轻,卡诺夫斯基功能状态(KPS)更高。与队列1(6.1个月)相比,队列2的中位总生存期明显更长(21.8个月)。队列2的局部和脑部复发率显著更高(<0.001),这归因于患者选择和更长的生存期。年龄和KPS的综合评分被证明是生存的预测因素,在总体人群中,年龄小于65岁且KPS>80的患者显示出最佳生存率。
这项回顾性研究强调,年龄和KPS的综合评分可以预测更好的生存,特别是对于年龄小于65岁且KPS评分高于80的患者。涉及更大和更多样化人群的进一步研究对于验证和扩展这些发现至关重要。